{'fraction_non_alphanumeric': 0.03134996801023673, 'fraction_numerical': 0.017914267434420986, 'mean_word_length': 4.835820895522388, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparative study between the effect of intravitreal injection of Ranibizumab and Aflibercept on macular oedema secondary to branch retinal vein occlusion

Background: Occlusion of retinal veins is a mutual disorder that affect the retina usually occurs when blood clot obstructs a retinal vein. Aim of The Work: To compare the effects of Ranibizumab versus Aflibercept intravitreal injections on macular edema (ME) caused by branch retinal vein occlusion (BRVO). Patients and Methods: This study was carried out on two groups of patients of either sex with an age ranging from 35 to 70 years. Every patient injected 3 loading doses. Ranibizumab dose is 0.5 mg dose vial (0.05 mL). Aflibercept dose is 2 mg dose vial (0.05 mL). Follow up was done 1st day post operation then monthly for 4 months. The eyes were followed for VA, IOP, OCT, FFA and any complications. Results: Both groups showed a significant reduction in central macular thickness (CMT) as well as an improvement in best-corrected visual acuity (BCVA). As regard CMT, the reduction and improvement in Aflibercept group was 71.6%, while the reduction and improvement in Ranibizumab group was 61.2%. Regarding to BCVA, the improvement in Aflibercept group was 70.8%, while the improvement in Ranibizumab group was 44.4%. The majority of the patients were satisfied from improvement of vision after injections. Conclusion: Both Ranibizumab and Aflibercept were efficient drugs in resolving ME secondary to BRVO with a superior improvement in VA and CMT in Aflibercept group compared with basal values.